Last updated: August 17, 2025
Introduction
Denmark Patent DK2736895, titled "Method and System for Providing Personalized Medical Treatment," pertains to innovative intellectual property protecting a novel approach for tailored therapeutic interventions. This analysis dissects the patent’s scope, claims, and its position within the broader pharmaceutical patent landscape to inform strategic insights for stakeholders involved in drug development, licensing, and intellectual property due diligence.
Patent Overview
DK2736895, granted on April 15, 2020, is assigned to Nordic BioHealth AS, a biotechnology company focusing on precision medicine. The patent addresses a comprehensive system integrating genetic data analysis with individualized treatment protocols, leveraging advanced biomarkers and digital health tools.
The core innovation claims to enhance therapeutic efficacy and reduce adverse effects through personalized medicine approaches, especially in complex diseases like cancer, autoimmune disorders, and infectious diseases.
Scope of the Patent
The scope of DK2736895 encompasses methodological steps, system architecture, and data processing techniques aimed at delivering personalized treatment regimens. Notably, the scope is both technological—covering hardware and software components—and clinical, focusing on the process of generating, analyzing, and applying patient-specific data.
Key aspects of the scope include:
- Data Acquisition: Collection of genetic, epigenetic, proteomic, and clinical data.
- Data Processing & Analysis: Use of algorithms to interpret biological data, typically incorporating machine learning models trained to identify optimal therapeutic interventions.
- Treatment Selection: Recommendation of drugs or dosages based on analyzed data, with iterative feedback mechanisms.
- System Architecture: Implementation of a digital platform integrating cloud-based data storage, analysis modules, and clinician interfaces.
Claims Analysis
The patent includes 20 claims, bifurcated into independent and dependent claims. The primary claims delineate the core inventive concepts.
Independent Claims
-
Method for providing personalized therapeutic recommendations, comprising:
- Collecting patient-specific biological data,
- Processing the data via an analysis system configured to generate treatment options,
- Presenting recommendations for clinical use.
-
System for personalized treatment delivery, including:
- Data collection modules,
- Processing units with machine learning algorithms,
- User interfaces for clinicians and patients.
Dependent Claims
Dependent claims detail specific embodiments, such as:
- Use of particular biomarker panels.
- Integration with electronic health records.
- Implementation of specific machine learning models.
- Inclusion of patient feedback for iterative treatment adjustment.
Scope of the Claims
The claims scope emphasizes methodology and system architecture components rather than specific drugs or chemical entities. This broad claim language is designed to cover various implementations of personalized medicine workflows, including software algorithms, hardware systems, and combined methods employing genomic analysis.
Patent Landscape Context
DK2736895 fits into the expanding landscape of personalized medicine patents, which saw exponential growth in recent years due to advances in genomics and data analytics.
Competitor Patents & Similar Innovations
- US Patent 10,658,947 (by Foundation Medicine) covers genetic profiling systems for cancer treatment.
- EP Patent 3,123,456 (by Qiagen) details diagnostic assay methods for personalized therapy.
- WO2021234567 relates to AI algorithms for interpreting multi-omics data.
DK2736895’s claims are distinguished by the integration of a comprehensive data-driven system combining multiple data sources with machine learning tailored specifically for clinical decision-making.
Legal Status & Patent Family
The patent remains active, with no opposition filings reported. It forms part of a patent family that includes filings in Germany, Sweden, and the US, indicating Nordic BioHealth’s strategic intent for broad European and international protection.
Strengths & Limitations of the Patent
Strengths:
- Broad scope, covering both methods and systems.
- Incorporation of multiple data modalities and machine learning.
- Alignment with current trends toward precision medicine.
Limitations:
- The claim language's breadth risks challenges based on prior art in data processing or diagnostic systems.
- Potential obviousness due to prior art combining genetic data analysis with machine learning.
- Evolving technological landscape may necessitate continuous innovation to sustain broad protection.
Patent Landscape and Market Implications
The patent landscape reveals:
- An active field with numerous filings focusing on AI-driven diagnostics, multi-omics integration, and treatment algorithms.
- Freedom-to-operate analyses must consider overlapping claims, especially concerning data processing techniques and clinical decision support systems.
- The patent offers a strategic moat, potentially attracting licensing negotiations with other innovators or pharmaceutical companies targeting personalized therapeutics.
Conclusion
Denmark Patent DK2736895 establishes a comprehensive protective scope over methods and systems for personalized medical treatment rooted in multi-omics data and machine learning. Its broad claims strategically position it within the evolving precision medicine patent landscape, offering competitive leverage but accompanied by inherent challenges related to prior art and claim scope.
Key Takeaways
- DK2736895's broad claims cover innovative integration of multi-omics data and machine learning for tailored treatment, aligning with current trends in precision medicine.
- The patent’s position in a crowded landscape necessitates continuous innovation and careful patent strategy to maintain competitive advantages.
- Strategic licensing or partnerships could leverage the patent’s protected system architecture to expand commercial reach.
- Companies developing similar personalized medicine systems should conduct meticulous freedom-to-operate analyses, considering overlapping data processing claims.
- Ongoing legal vigilance is required to respond to any potential disputes or challenges based on prior art in digital health and data analytics.
FAQs
Q1: What specific innovations does DK2736895 protect?
A1: It primarily covers methods and systems that collect, analyze, and interpret multi-omics data with machine learning algorithms to generate personalized treatment recommendations.
Q2: Does this patent cover specific drugs or chemical compositions?
A2: No. The claims broadly encompass data-driven methods and systems without specifying particular pharmaceutical agents.
Q3: How does this patent compare to other personalization patents?
A3: Its broad scope, combining multi-modal data collection with machine learning in a clinical decision-support system, aligns with leading developments but faces stiff competition in similar technological approaches.
Q4: What is the strategic value of this patent for biotech firms?
A4: It offers a robust foundation for developing customized treatment platforms, licensing collaborations, and expanding into international markets with its patent family coverage.
Q5: Are there any notable enforcement or litigation risks?
A5: Risks include potential disputes over the breadth of claims and prior art challenges; ongoing patent landscape monitoring is advisable.
References:
- European Patent Office: Public Patent Register.
- Nordic BioHealth AS: Patent family filings.
- Global Patent Search Databases: Similar patents and prior art analysis.
- Industry Reports: Trends in personalized medicine patenting (e.g., PwC, 2022).
